Staar Surgical CoSTAA -5.21%79 Days Payable is 37.50 as of Mar. 2026, which is 47% below its 10-year median of 70.10. GuruFocus rates STAA with a GF Score™ of 79/100 and a GF Value™ of $31.39 (Fairly Valued). The stock has 7 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Staar Surgical Co ranks worse than 60.75% on this metric.
The historical rank and industry rank for Staar Surgical Co's Days Payable or its related term are showing as below:
STAA'
s Days Payable Range Over the Past 10 Years
Min: 56.94 Med: 70.1 Max: 113.78
Current: 57.94
During the past 13 years, Staar Surgical Co's highest Days Payable was 113.78. The lowest was 56.94. And the median was 70.10.
STAA's Days Payable is ranked worse than 60.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs STAA: 57.94
Staar Surgical Co's Days Payable
declined
from Mar. 2025 (88.12) to Mar. 2026 (37.50).
It may suggest that Staar Surgical Coaccelerated paying its suppliers.
Staar Surgical Co Days Payable Related Terms
Staar Surgical Co Days Payable Historical Data
* Premium members only.
The historical data trend for Staar Surgical Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Staar Surgical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staar Surgical Co (STAA) has a Days Payable of 37.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Staar Surgical Co and its competitors. This is 47% below median its historical median of 70.10. Over the past decade, Staar Surgical Co's Days Payable has ranged from 56.94 to 113.78. According to the industry distribution chart, Staar Surgical Co ranks #483 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 60.8%.
Is Staar Surgical Co's Days Payable too high?
Staar Surgical Co's current Days Payable of 37.50 is 47% below median its 10-year median of 70.10. Over the past 10 years, this metric has ranged from a low of 56.94 to a high of 113.78. The Medical Devices & Instruments industry median Days Payable is 67.87. Staar Surgical Co's value of 37.50 is 44.7% below this industry median. Based on the distribution chart, Staar Surgical Co ranks #483 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Staar Surgical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's Days Payable compare to NNNN and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Staar Surgical Co ranks #483 out of 795 companies for Days Payable. This places Staar Surgical Co in the lower half of its industry. The industry median Days Payable is 67.87. Staar Surgical Co's value of 37.50 is 44.7% below this benchmark. Historically, Staar Surgical Co's own Days Payable has ranged from 56.94 to 113.78 over the past decade. While the company's 10-year median is 70.10 vs. the industry median of 67.87, Staar Surgical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Staar Surgical Co's current Days Payable of 37.50 is 44.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Staar Surgical Co and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Staar Surgical Co's current Days Payable is 37.50, which is 47% below median its own 10-year median of 70.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (STAA) is currently considered Fairly Valued. The stock's GF Value™ is $31.39, compared to a current price of $29.58 — trading 5.8% below its estimated fair value. The current Days Payable is 37.50, which is 47% below median its 10-year median of 70.10 and 44.7% below the Medical Devices & Instruments industry median of 67.87. Staar Surgical Co's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Staar Surgical Co (STAA), the current Days Payable is 37.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (STAA) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of $29.58 is trading 5.8% below its estimated GF Value™ of $31.39.
GuruFocus considers Staar Surgical Co to be Fairly Valued.
Key valuation signals for STAA:
Days Payable: 37.50 (47% below median its 10-year median of 70.10)
GF Value™: $31.39 vs. price of $29.58 (5.8% below fair value)
Industry Position: 44.7% below the Medical Devices & Instruments median (#483 of 795)
No single metric tells the full story. See the STAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
79GF Score
Get the complete analysis for STAA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STAA has been successfully added to your 
